ARMO BioSciences (ARMO) IPO Opens Up 65%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil prices gain more than 3%, heading for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Vertiv shares fall on analyst downgrades and options bets
- Stocks edge lower as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
ARMO BioSciences Announces Pricing of Initial Public Offering
January 25, 2018 9:09 PM ESTREDWOOD CITY, Calif., Jan. 25, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. ("ARMO"), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of approximately $128.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market on January 26, 2018 under the ticker symbol "ARMO." The offering is expected to close on January 30, 2018, subject to customary closing conditions.
In addition, ARMO has granted the underwriters a 30-day option to purchase up to an additional... More



